Some of these products are not FDA cleared. Please contact your sales representative for more information.
Product claims may differ from country to country based on regulations and product approvals.
Please contact your country representative for further details.
Thermo Fisher Scientific
Tel: +49 - 3302 - 883 - 0
Fax: +49 - 3302 - 883 - 100
Im Rahmen einer Projektförderung des Landes Brandenburg, vertreten durch die Zukunftsagentur Brandenburg (ZAB) sowie die Investitionsbank des Landes Brandenburg (ILB), erhielt Thermo Fisher Scientific Fördermittel des Europäischen Fonds für regionale Entwicklung (EFRE). In zwei Forschungs- und Entwicklungsprojekten wurden im Zeitraum von April 2009 bis Dezember 2013 innovative Lösungen für die medizinische Diagnostik erarbeitet.
“Biomarkers in Cardiology 8” study published in European Heart Journal HENNIGSDORF, Germany – (June 17, 2014) – A study conducted by clinicians in leading German, Swiss and Austrian hospitals demonstrates that low-to-intermediate risk patients with suspected Acute Coronary Syndrome (ACS) can safely be discharged earlier from the Emergency Department (ED) using cardiac Troponin together with Copeptin. The study suggests that, by implementing the new process, clinics can better manage overcrowded EDs and increase patient well-being.
-- Company expands cardiovascular pipeline and aims to address large unmet need for prognosis and risk stratification in patients with heart failure --SOUTH SAN FRANCISCO, Calif.- (March 05, 2014) - diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced an exclusive licensing and supply agreement with Thermo Fisher Scientific Inc., the world leader in serving science with $17 billion in revenues, that will provide diaDexus with the ability to develop and commercialize three independent biomarkers (MR-proADM (midregional pro adrenomedullin), MR-proANP (midregional pro atrial natriuretic peptide), and CT-proET1 (C-terminal pro endothelin-1)) to aid in risk prediction and prognosis for heart failure.
Marcy l'Etoile, France and Hennigsdorf, Germany (October 2, 2012) – bioMérieux and Thermo Fisher Scientific Inc., the world leader in serving science, today announced they have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin (PCT) testing. This agreement extends a long-standing relationship between the companies for biomarker testing using Thermo Fisher’s PCT product on bioMérieux’s VIDAS® and mini VIDAS® immunoassay platforms, and now also includes the new-generation VIDAS® products.
(WALTHAM, MA – September 24, 2013) – Thermo Fisher Scientific applauds the tenacity of the Staunton family, as well as Chairman Tom Harkin and Ranking Member Lamar Alexander, for raising the profile of sepsis education among the public, legislators and other government officials.